Bioanalytical challenges and strategies of T-cell engager therapeutics
Decoding bioanalytical challenges in T-cell engager therapeutics.
T-cell engager (TCE) therapeutics represent an exciting frontier in oncology and immunotherapy, but their complex structure and mechanism of action create unique challenges for bioanalysis. This webinar will provide an overview of the background of TCE therapeutics, followed by a deep dive into bioanalytical considerations across pharmacokinetics, immunogenicity (ADA and NAb) and biomarker analysis. Case studies and assay strategies will be highlighted to illustrate practical solutions for overcoming these challenges and ensuring robust, regulatory-ready data to support drug development.
What will you learn?
- Gain an overview of TCE therapeutic mechanisms and their growing role in oncology and immunotherapy
- Understand the unique bioanalytical challenges of TCEs across pharmacokinetics, immunogenicity (ADA and NAb) and biomarker analysis
- Explore assay formats and strategies tailored to overcome complexity in TCE bioanalysis
- Review real-world case studies illustrating practical solutions and lessons learned
- Learn more about generating robust, regulatory-ready bioanalytical data to accelerate TCE development
Who may this interest?
-
Bioanalytical scientists and business executives in the pharmaceutical industry who have bispecific antibody therapeutic products/projects in their pipelines.
Xin Ning
Senior Scientist II
WuXi AppTec LTD (Shanghai, China)
Dr Xin Ning received his PhD at the end of 2020 and joined the Bioanalytical Services team at WuXi AppTec in March 2021. He has served as an Analyst, Principal Investigator and Project Manager in the last 4 years. His job responsibilities now are to provide technical evaluation and quotation on new large molecule projects and act as Project Manager for clinical studies.
This webinar was recorded on the 16th of October 2025.
In association with:
